A Phase 1 Open Label Crossover Study to assess safety and bioavailability of ML-004-ER under Fasted and Fed Conditions in Adult Healthy Volunteers
Latest Information Update: 11 Oct 2021
At a glance
- Drugs ML-004 (Primary)
- Indications Autistic disorder
- Focus Pharmacokinetics
- Sponsors Accelagen Pty Ltd; MapLight Therapeutics
Most Recent Events
- 07 Oct 2021 Status changed from not yet recruiting to recruiting.
- 20 Apr 2021 Status changed from recruiting to not yet recruiting.
- 05 Dec 2020 New trial record